RA 101495

Drug Profile

RA 101495

Alternative Names: RA101495

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ra Pharmaceuticals
  • Class Cyclic peptides; Macrocyclic compounds
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Preclinical Lupus nephritis; Myasthenia gravis

Most Recent Events

  • 31 Jul 2017 RA 101495 receives Orphan Drug status for Paroxysmal nocturnal haemoglobinuria in USA
  • 27 Jun 2017 Initial safety and efficacy data from a phase II trial in Paroxysmal nocturnal haemoglobinuria released by Ra Pharmaceuticals
  • 17 Mar 2017 Phase-II clinical trials in Paroxysmal nocturnal haemoglobinuria in Hungary (SC) (EudraCT2016-003523-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top